For the quarter ending 2025-09-30, EBS made $231,100K in revenue. $51,200K in net income. Net profit margin of 22.15%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 231,100 | 140,900 | 222,200 | 249,933 |
| Cost of product and services sales, net | 85,900 | 66,900 | 88,500 | 21,100 |
| Research and development | 13,500 | 12,500 | 15,100 | 18,967 |
| Selling, general and administrative | 38,900 | 43,700 | 52,400 | 179,800 |
| Amortization of intangible assets | 16,300 | 16,200 | 16,300 | 47,000 |
| Impairment of long-lived assets | 0 | 0 | - | 40,800 |
| Total operating expenses | 154,600 | 139,300 | 172,300 | 307,667 |
| Income (loss) from operations | 76,500 | 1,600 | 49,900 | -57,733 |
| Interest expense | 15,200 | 14,700 | 14,700 | 20,900 |
| Gain (loss) on sale of business and assets held for sale | 0 | - | - | -13,333 |
| Loss on assets held for sale | - | 0 | -12,200 | - |
| Other, net | -3,700 | -3,700 | 69,700 | -3,133 |
| Total other income (expense), net | -18,900 | -18,400 | 42,800 | -37,367 |
| Income (loss) before income taxes | 57,600 | -16,800 | 92,700 | -95,100 |
| Income tax provision | 6,400 | -4,800 | 24,700 | 6,700 |
| Net income (loss) | 51,200 | -12,000 | 68,000 | -101,800 |
| Basic (in dollars per share) | 0.96 | -0.22 | 1.25 | -1.92 |
| Basic (in shares) | 53,200,000 | 54,200,000 | 54,400,000 | -33,333.333 |
| Diluted (in dollars per share) | 0.91 | -0.22 | 1.19 | -1.887 |
| Diluted (in shares) | 56,500,000 | 54,200,000 | 57,300,000 | -866,666.667 |
Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. (EBS)